Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has approved an update for the label for Qelbree to ...

ROCKVILLE, Md. - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company specializing in CNS diseases with an impressive 89% gross profit margin, has announced the FDA approval of a ...

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) stock has reached a new 52-week high, touching $39.38 as the company continues to show robust performance in the pharmaceutical sector. According to ...

Equities research analysts at Cantor Fitzgerald initiated coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) in a research report issued to clients and investors on Monday, ...

If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the ...

SUPN insiders have traded $SUPN stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales. Here’s a ...

After hours: January 24 at 5:29:32 PM EST Loading Chart for SUPN ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The updated labeling for Qelbree provides additional information on the pharmacodynamic profile of the drug. Findings show ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.